Dataset related to article "The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group "
Creators
-
Ciro Franzese1
- Giulia Marvaso2
- Giulio Francolini3
- Paolo Borghetti4
- Luca Eolo Trodella5
- Matteo Sepulcri6
- Fabio Matrone7
- Luca Nicosia8
- Giorgia Timon9
- Lucia Ognibene10
- Annamaria Vinciguerra11
- Filippo Alongi12
- Roberto Bortolus7
- Luigi Corti6
- Sara Ramella5
- Stefano Maria Magrini4
- Lorenzo Livi3
- Barbara Alicja Jereczek-Fossa13
-
Marta Scorsetti1
- Stefano Arcangeli14
- 1. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 2. Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy.
- 3. Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
- 4. Radiation Oncology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
- 5. Radiation Oncology, Campus Bio-Medico University, University of Rome, Rome, Italy.
- 6. Department of Radiation Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
- 7. Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
- 8. Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Italy.
- 9. Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- 10. Radiotherapy Unit, San Gaetano Radiotherapy and Nuclear Medicine Center, Palermo, Italy.
- 11. Department of Radiation Oncology "G. D'Annunzio", University of Chieti, SS. Annunziata Hospital, Chieti, Italy.
- 12. Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Italy. AND University of Brescia, Brescia, Italy.
- 13. Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy. AND Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
- 14. UOC Radioterapia ASST Monza, Università di Milano, Bicocca, Italy.
Description
This record contains raw data related to article “The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group"
Although systemic therapy represents the standard of care for polymetastatic kidney cancer, stereotactic body radiation therapy (SBRT) may play a relevant role in the oligometastatic setting. We conducted a multicenter study including oligometastatic kidney cancer treated with SBRT. We retrospectively analyzed 207 patients who underwent 245 SBRT treatments on 385 lesions, including 165 (42.9%) oligorecurrent (OR) and 220 (57.1%) oligoprogressive (OP) lesions. Most common sites were lung (30.9%) for OR group, and bone (32.7%) for OP group. Among 78 (31.8%) patients receiving concomitant systemic therapy, sunitinib (61.5%) and pazopanib (15.4%) were the most common for OR patients, while sunitinib (49.2%) and nivolumab (20.0%) for OP patients. End points were local control (LC), progression free survival (PFS), overall survival (OS), time to next systemic therapy (TTNS) and toxicity. Median follow-up was 18.6 months. 1, 2 and 3-year LC rates were 89.4%, 80.1% and 76.6% in OR patients, and 82.7%, 76.9% and 64.3% in those with OP, respectively. LC for OP group was influenced by clear cell histology (p = 0.000), total number of lesions (p = 0.004), systemic therapy during SBRT (p = 0.012), and SBRT dose (p = 0.012). Median PFS was 37.9 months. 1, 2- and 3-year OS was 92.7%, 86.4% and 81.8%, respectively. Median TTNS was 15.8 months for OR patients, and 13.9 months for OP patients. No grade 3 or higher toxicities were reported for both groups. SBRT may be considered an effective safe option in the multidisciplinary management of both OR and OP metastases from kidney cancer.
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of raw data is accessible under request because they include sensitive data.
Please write your request at biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- 34748125 (PMID)
- 10.1007/s10585-021-10131-w (DOI)